Literature DB >> 23331572

Schwann cell-mediated delivery of glial cell line-derived neurotrophic factor restores erectile function after cavernous nerve injury.

Florian May1, Alexander Buchner, Boris Schlenker, Christian Gratzke, Christian Arndt, Christian Stief, Norbert Weidner, Kaspar Matiasek.   

Abstract

OBJECTIVES: To evaluate the time-course of functional recovery after cavernous nerve injury using glial cell line-derived neurotrophic factor-transduced Schwann cell-seeded silicon tubes.
METHODS: Sections of the cavernous nerves were excised bilaterally (5 mm), followed by immediate bilateral surgical repair. A total of 20 study nerves per group were reconstructed by interposition of empty silicon tubes and silicon tubes seeded with either glial cell line-derived neurotrophic factor-overexpressing or green fluorescent protein-expressing Schwann cells. Control groups were either sham-operated or received bilateral nerve transection without nerve reconstruction. Erectile function was evaluated by relaparotomy, electrical nerve stimulation and intracavernous pressure recording after 2, 4, 6, 8 and 10 weeks. The animals underwent re-exploration only once, and were killed afterwards. The nerve grafts were investigated for the maturation state of regenerating nerve fibers and the fascular composition.
RESULTS: Recovery of erectile function took at least 4 weeks in the current model. Glial cell line-derived neurotrophic factor-transduced Schwann cell grafts restored erectile function better than green fluorescent protein-transduced controls and unseeded conduits. Glial cell line-derived neurotrophic factor-transduced grafts promoted an intact erectile response (4/4) at 4, 6, 8 and 10 weeks that was overall significantly superior to negative controls (P < 0.001). Maximum intracavernous pressure on electrostimulation was significantly elevated using glial cell line-derived neurotrophic factor-transduced grafts compared with negative controls (P = 0.018) and unseeded tubes (P = 0.034). Return of function was associated with the electron microscopic evidence of preganglionic myelinated nerve fibers and postganglionic unmyelinated axons.
CONCLUSIONS: Schwann cell-mediated delivery of glial cell line-derived neurotrophic factor presents a viable approach for the treatment of erectile dysfunction after cavernous nerve injury.
© 2013 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331572     DOI: 10.1111/iju.12078

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

Review 1.  A review of bioactive release from nerve conduits as a neurotherapeutic strategy for neuronal growth in peripheral nerve injury.

Authors:  Poornima Ramburrun; Pradeep Kumar; Yahya E Choonara; Divya Bijukumar; Lisa C du Toit; Viness Pillay
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

2.  3D printed nerve guidance channels: computer-aided control of geometry, physical cues, biological supplements and gradients.

Authors:  Blake N Johnson; Xiaofeng Jia
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

3.  Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells Reduces Erectile Dysfunction Following Cavernous Nerve Injury in Rats.

Authors:  Yohei Matsuda; Masanori Sasaki; Yuko Kataoka-Sasaki; Akio Takayanagi; Ko Kobayashi; Shinichi Oka; Masahito Nakazaki; Naoya Masumori; Jeffery D Kocsis; Osamu Honmou
Journal:  Sex Med       Date:  2017-12-21       Impact factor: 2.491

4.  Local continuous glial cell derived neurotrophic factor release using osmotic pump promotes parasympathetic nerve rehabilitation in an animal model of cavernous nerve injury induced erectile dysfunction.

Authors:  Huixi Li; Zhichao Zhang; Dong Fang; Yuan Tang; Jing Peng
Journal:  Transl Androl Urol       Date:  2021-01

5.  Cavernous nerve reconstruction with autologous vein graft and platelet-derived growth factors.

Authors:  Xie-Gang Ding; Shi-Wen Li; Xin-Min Zheng; Xing-Huan Wang; Yi Luo
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.